Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
China Pharma Univ. Wee1 compound 12h
- Development stage
- Preclinical
- Lead developer
- China Pharmaceutical University
01
Overview
China Pharma Univ. Wee1 compound 12h: sourced facts only. name: "Here, we report the discovery of 12h, a highly selective and potent Wee1 inhibitor with a favorable pharmacokinetic profile." [PMID:38847373]; target: "Here, we report the discovery of 12h, a highly selective and potent Wee1 inhibitor with a favorable pharmacokinetic profile." [PMID:38847373]; developer: "School of Sciences, China Pharmaceutical University, 639 Longmian Avenue, Nanjing 211198, P.R. China." [PMID:38847373]; stage: "12h showed strong antiproliferative effects against Lovo cells, a colorectal cancer cell line, both in vitro and in vivo." [PMID:38847373]
02
Targets
WEE1 (WEE1 G2 checkpoint kinase)
Beyond the preview
Go deeper on China Pharma Univ. Wee1 compound 12h.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on China Pharma Univ. Wee1 compound 12h.